-
Mashup Score: 24Quality Care Symposium - ASCO - 6 day(s) ago
location_on Marriott Marquis Chicago, Chicago IL & Online Showcase your work for advancing quality cancer care. Contribute your solutions-orie nted research to the 2025 ASCO Quality Care Symposium—the premier meeting addressing the quality, safety, and efficiency in cancer care delivery.
Source: www.asco.orgCategories: General Medicine NewsTweet
-
Mashup Score: 42025 Conquer Cancer Grants & Awards - ASCO - 6 day(s) ago
location_on McCormick Place, Chicago, IL & Online Launched in 2016, this award program honors extraordinary women leaders in oncology and role models who have excelled as mentors and have demonstrated outstanding commitment to the development of the next generation of cancer researchers and leaders. Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award W. Kimryn Rathmell, MD, PhD, MMHC, FASCO, The Ohio State University International Women Who Conquer Cancer Mentorship Award Nazik Hammad, MD,
Source: www.asco.orgCategories: General Medicine NewsTweet-
Congrats to these @OSUCCC_James experts and @OhioStateMed students on their well-deserved @ASCO recognition. https://t.co/HT5k9182Bg
-
-
Mashup Score: 21Submission Details - ASCO - 7 day(s) ago
location_on Marriott Marquis Chicago, Chicago IL & Online View detailed information below on submitting an abstract including submission categories, guidelines, and policies.
Source: www.asco.orgCategories: General Medicine News, Partners & KOLsTweet-
It’s crunch time! Finish up & submit that abstract to #ASCOQLTY25 on your data-driven approaches & scalable interventions that can improve the quality of #CancerCare. Consider leveraging your existing #ASCO25 data & submitting a #QoL endpoint analysis: https://t.co/oU9xGtXjat https://t.co/t8mymduFLs
-
-
Mashup Score: 24Quality Care Symposium - ASCO - 7 day(s) ago
location_on Marriott Marquis Chicago, Chicago IL & Online Showcase your work for advancing quality cancer care. Contribute your solutions-orie nted research to the 2025 ASCO Quality Care Symposium—the premier meeting addressing the quality, safety, and efficiency in cancer care delivery.
Source: www.asco.orgCategories: General Medicine NewsTweet-
🚨 Deadline Alert! 📅 June 10: Abstract submissions close for the #ASCOQLTY25 Share your solutions-driven research and help shape the future of quality cancer care. Don’t miss the premier forum for innovation in care delivery 🔗https://t.co/GECWE5x16L https://t.co/kDbrubgkql
-
-
Mashup Score: 23Quality Care Symposium - ASCO - 9 day(s) ago
location_on Marriott Marquis Chicago, Chicago IL & Online Showcase your work for advancing quality cancer care. Contribute your solutions-orie nted research to the 2025 ASCO Quality Care Symposium—the premier meeting addressing the quality, safety, and efficiency in cancer care delivery.
Source: www.asco.orgCategories: General Medicine NewsTweet-
🚨 Deadline Alert! 📅 June 10: Abstract submissions close for the #ASCOQLTY25 Share your solutions-driven research and help shape the future of quality cancer care. Don’t miss the premier forum for innovation in care delivery 🔗https://t.co/GECWE5x16L https://t.co/kDbrubgkql
-
-
Mashup Score: 18Open Comment of Guidelines - ASCO - 11 day(s) ago
Open comment allows key stakeholders to critically review and identify any errors or gaps in a draft guideline prior to its finalization and publication. It allows for greater transparency in the ASCO guideline development process and complies with the Institute of Medicine (IOM) and Counc il for Medical Specialty Societies (CMSS) standards for guideline development. In addition, open comment enables ASCO to engage interested stakeholders (especially patients/patient advocacy groups), provide a higher-qual
Source: www.asco.orgCategories: General Medicine News, Partners & KOLsTweet-
The draft guideline protocol, #palliativecare in the global setting, is now available for open comment. Provide your feedback to us by June 18. Learn more: https://t.co/QTqLM5tPLA https://t.co/qerNcq2CRa
-
-
Mashup Score: 40ASCO Annual Meeting - Research Summaries for Patients - ASCO - 12 day(s) ago
From May 30 to June 3 in Chicago, Illinois, and online, cancer researchers and clinicians from around the world will gather for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. They will attend over 200 sessions centered around the theme of this year’s meeting: Driving Knowledge to Action: Building a Better
Source: www.asco.orgCategories: General Medicine NewsTweet-
Want to share practice-changing research from #ASCO25 with your patients? 18 summaries highlighting key studies in #BreastCancer, #ColorectalCancer, #LungCancer, and more are available NOW: https://t.co/QGcppO7AWd https://t.co/ojLVlDwdXI
-
-
Mashup Score: 12GLP-1 Receptor Agonists May Modestly Reduce Risk of Fourteen Obesity-Related Cancers for People with Diabetes - ASCO - 13 day(s) ago
“This trial raises an intriguing hypothesis: that the increasingly popular GLP-1 medications used to treat diabetes and obesity might offer some benefit in reducing the risk of developing cancer. I see many patients with obesity, and given the clear link between cancer and obesity, defining the clinical role of GLP-1 medications in cancer prevention is important. Though this trial does not establish causation, it hints that these drugs might have a preventative effect. Future research is needed to
Source: www.asco.orgCategories: General Medicine NewsTweet-
GLP-1 Receptor Agonists May Modestly Reduce Risk of Fourteen Obesity-Related Cancers for People with Diabetes https://t.co/zsC4e5PxkE https://t.co/dR5glWmijq
-
-
Mashup Score: 31Maintenance therapy with lurbinectedin and atezolizumab helps patients with extensive-stage small cell lung cancer live longer - ASCO - 13 day(s) ago
Who does this study affect? Patients with extensive-stage small cell lung cancer (ES-SCLC) that has been previously treated What did this study find? The phase 3 IMforte study found that patients with ES-SCLC previously treated with atezolizumab (Tecentriq) and chemotherapy lived longer if they received maintenance therapy with a combination of lurbinectedin (Zepzelca) and atezolizumab. This was compared to the current standard-of-care maintenance therapy of atezolizumab alone. SCLC is an aggressive form
Source: www.asco.orgCategories: General Medicine News, Partners & KOLsTweet-
Breaking cancer news from #ASCO25: IMforte clinical trial shows lurbinectedin + atezolizumab as first-line maintenance therapy for extensive-stage #SCLC helps patients live months longer. Learn more: https://t.co/S4UPXS9rig #LCSM @luispaz_ares https://t.co/DJSyZvnBIl
-
-
Mashup Score: 46GLP-1 receptor agonists may modestly reduce risk of 14 obesity-related cancers for people with diabetes - ASCO - 14 day(s) ago
Who does this study affect? Adults with obesity and diabetes What did this study find? A large observational study of more than 170,000 people with diabetes and obesity found that treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist may modestly reduce the risk of 14 obesity-related cancers. Treatment with a GLP-1 receptor agonist was also associated with a lower risk of death due to all causes. This was in comparison to another diabetes medication called a dipeptidyl peptidase-4 (DDP-4)
Source: www.asco.orgCategories: General Medicine News, Partners & KOLsTweet-
Breaking research on GLP-1s and cancer from #ASCO25: For people with obesity and #diabetes, GLP-1 receptor agonists are associated with a modestly lower risk of obesity-related cancers, especially colorectal cancer. Learn more: https://t.co/1OQLRR8Ub5 https://t.co/5mz9arZ6Gp
-
🚨 Deadline Alert! 📅 June 10: Abstract submissions close for the #ASCOQLTY25 Share your solutions-driven research and help shape the future of quality cancer care. Don’t miss the premier forum for innovation in care delivery 🔗https://t.co/GECWE5x16L https://t.co/kDbrubgkql